189 related articles for article (PubMed ID: 36879495)
1. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.
Lu B; Wong M; Ha D; Bounthavong M; Banaei N; Deresinski S; Diep C
J Antimicrob Chemother; 2023 Apr; 78(4):1009-1014. PubMed ID: 36879495
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems.
Tan SH; Ng TM; Chew KL; Yong J; Wu JE; Yap MY; Heng ST; Ng WHW; Wan S; Cheok SJH; Tambyah PA; Lye DC
Int J Antimicrob Agents; 2020 Feb; 55(2):105860. PubMed ID: 31841674
[TBL] [Abstract][Full Text] [Related]
3. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility evolution to antibiotics of Enterobacter cloacae, Morganella morganii, Klebsiella aerogenes and Citrobacter freundii involved in urinary tract infections: an 11-year epidemiological surveillance study.
Jiménez-Guerra G; Borrego-Jiménez J; Gutiérrez-Soto B; Expósito-Ruiz M; Navarro-Marí JM; Gutiérrez-Fernández J
Enferm Infecc Microbiol Clin (Engl Ed); 2020 Apr; 38(4):166-169. PubMed ID: 31606242
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
Maillard A; Delory T; Bernier J; Villa A; Chaibi K; Escaut L; Contejean A; Bercot B; Robert J; El Alaoui F; Tankovic J; Poupet H; Cuzon G; Lafaurie M; Surgers L; Joseph A; Paccoud O; Molina JM; Bleibtreu A;
Int J Antimicrob Agents; 2023 Jul; 62(1):106809. PubMed ID: 37028731
[TBL] [Abstract][Full Text] [Related]
6. Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing
Benanti GE; Brown ART; Shigle TL; Tarrand JJ; Bhatti MM; McDaneld PM; Shelburne SA; Aitken SL
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509935
[TBL] [Abstract][Full Text] [Related]
7. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing
Stewart AG; Paterson DL; Young B; Lye DC; Davis JS; Schneider K; Yilmaz M; Dinleyici R; Runnegar N; Henderson A; Archuleta S; Kalimuddin S; Forde BM; Chatfield MD; Bauer MJ; Lipman J; Harris-Brown T; Harris PNA;
Open Forum Infect Dis; 2021 Aug; 8(8):ofab387. PubMed ID: 34395716
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem.
Holsen MR; Wardlow LC; Bazan JA; Fussner LA; Coe KE; Elefritz JL
Int J Antimicrob Agents; 2019 Dec; 54(6):824-828. PubMed ID: 31319191
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Bacteremia Caused by
Drozdinsky G; Neuberger A; Rakedzon S; Nelgas O; Cohen Y; Rudich N; Mushinsky L; Ben-Zvi H; Paul M; Yahav D
Microb Drug Resist; 2021 Mar; 27(3):410-414. PubMed ID: 32808858
[No Abstract] [Full Text] [Related]
10. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.
Stewart AG; Harris PNA; Chatfield MD; Littleford R; Paterson DL
Trials; 2021 Apr; 22(1):301. PubMed ID: 33888139
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
[TBL] [Abstract][Full Text] [Related]
12. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
Ng TM; Khong WX; Harris PN; De PP; Chow A; Tambyah PA; Lye DC
PLoS One; 2016; 11(4):e0153696. PubMed ID: 27104951
[TBL] [Abstract][Full Text] [Related]
13. Induction of plasmid-mediated AmpC β-lactamase DHA-1 by piperacillin/tazobactam and other β-lactams in Enterobacteriaceae.
Akata K; Muratani T; Yatera K; Naito K; Noguchi S; Yamasaki K; Kawanami T; Kido T; Mukae H
PLoS One; 2019; 14(7):e0218589. PubMed ID: 31283769
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
[TBL] [Abstract][Full Text] [Related]
15. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE).
Pfaller MA; Jones RN; Marshall SA; Coffman SL; Hollis RJ; Edmond MB; Wenzel RP
Diagn Microbiol Infect Dis; 1997 Aug; 28(4):211-9. PubMed ID: 9327251
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?
Harris PN; Ferguson JK
Int J Antimicrob Agents; 2012 Oct; 40(4):297-305. PubMed ID: 22824371
[TBL] [Abstract][Full Text] [Related]
17. Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.
Cheng L; Nelson BC; Mehta M; Seval N; Park S; Giddins MJ; Shi Q; Whittier S; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320724
[No Abstract] [Full Text] [Related]
18. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
[TBL] [Abstract][Full Text] [Related]
19. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and diversity of qnr alleles in AmpC-producing Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Serratia marcescens: a multicentre study from Korea.
Park YJ; Yu JK; Lee S; Oh EJ; Woo GJ
J Antimicrob Chemother; 2007 Oct; 60(4):868-71. PubMed ID: 17660263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
